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○ When in doubt:
■ Move more weight
■ Eat more protein
Objectives 
● Define sarcopenia as a clinical diagnosis as described by the European 
Working Group on Sarcopenia in Older Persons (EWGSOP2)
● Recognize, identify, and describe sarcopenia as a distinct disease process
● Review impact on health outcomes and healthcare costs
● Explain tools used to aid in diagnosis in clinical practice
● Explore the nuances of therapeutic interventions
● Discuss role of the primary care physician
What we will cover
● Definition of sarcopenia as laid out by the European Working Group on 
Sarcopenia in Older People 2018 (EWGSOP2)
● Related adverse health outcomes and healthcare costs
● Ways to diagnose sarcopenia in clinical practice 
● Current paradigms of treatment of sarcopenia with focus mainly on primary 
sarcopenia
What we will NOT cover
● In-depth discussion of various forms of sarcopenia (secondary sarcopenia, 
sarcopenic obesity, etc.) 
● Comprehensive review of cachexia and frailty 
● In-depth analysis of biochemical basis of sarcopenia 
● Complex diagnostic tests or possible future tests or therapeutic targets
Outline
● What is sarcopenia?
○ Definition provided by EWGSOP2
○ Brief overview of pathophysiology 
● Why is it important?
○ Epidemiology 
○ Impact on health outcomes 
○ Healthcare costs 
● Diagnosis 
○ Review EWGSOP2 framework for clinical practice
○ Questionnaires
○ Office based testing 
○ Imaging 
● Treatment and Prevention
○ Dietary interventions 
○ Exercise Interventions 
○ Role of PCP
What is sarcopenia?
What is sarcopenia? Definitions
● Greek etymology 
● “Poverty of flesh”
● “Sarco” = “flesh”
● “Penia” = deficiency or poverty 
What is sarcopenia? Definitions 
● Muscle disease rooted in adverse muscle changes that accrue across a lifetime defined by low 
levels of:
○ Muscle strength 
○ Muscle quantity/quality 
○ Physical performance as an indicator of severity 
● “Muscle failure"
European Working Group on Sarcopenia in Older Persons 
(EWGSOP) 
● Organized by European Geriatric Medicine Society (EuGMS)
● First meeting (EWGSOP1) - 2010
● Second meeting (EWGSOP2) - 2018 
● Final content and recommendations reviewed and endorsed by many 
organizations
○ EuGMS
○ European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and 
Musculoskeletal Diseases (ESCEO)
○ European Society for Clinical Nutrition and Metabolism (ESPEN)
○ International Osteoporosis Foundation (IOF)
○ Among others
European Working Group on Sarcopenia in Older Persons - 2010
● Paradigm shift 
○ Muscle function = key element
● Former definitions
○ Based only on low muscle mass
European Working Group on Sarcopenia in Older Persons - 2018
● Strength comes to the forefront
○ Better predictor of adverse 
outcomes
○ Difficult to measure muscle quantity 
& quality in practice
● Quality as important as quantity 
● Physical performance 
○ Part of core definition vs 
outcome measure
○ Use to grade severity 
What is sarcopenia? Pathophysiology - Strength  
What is sarcopenia? Pathophysiology - Strength
● Development of strength accelerates during adolescence 
● Males
○ Peaks between age 29-39
○ Mean peak in grip strength 51kg 
● Females 
○ Peaks between age 26-42
○ Mean peak in grip strength is 31kg 
● Decline after age 50
○ 1.5-5% decline in strength per year
○ 1-2% decline in muscle mass per year 
What is sarcopenia? Pathophysiology - Biochemistry
What is sarcopenia? Pathophysiology - Biochemistry
What is sarcopenia? Sarcopenia vs Cachexia
● Cachexia
○ Complex metabolic syndrome 
associated with underlying illness
○ Loss of muscle mass with or 
without loss of fat mass
○ Associated with inflammation, 
insulin resistance, and anorexia
○ Most cachectic individuals are 
sarcopenic
● Sarcopenia
○ Skeletal muscle disorder 
characterized by loss of strenght 
and muscle mass
○ Most sarcopenic patients are not 
cachectic 
■ Ex: Sarcopenic obesity
What is sarcopenia? Sarcopenia vs Frailty
● Frailty
○ Multidimensional geriatric 
syndrome
○ Physical and social dimensions
● Sarcopenia
○ Distinct disease process
○ Contributor to physical frailty
Why is it important?
If the body be feeble, the mind will not be 
strong. The sovereign invigorator of the body 
is exercise...Not less than two hours a day 
should be devoted to exercise.
-Thomas Jefferson to Thomas Mann Randolph, August 
1786
Why is it important? Epidemiology 
● UK Study 
○ Prevalence 
■ 4.6% in men
■ 7.9% in women
○ Average age 67
● US study
○ Prevalence = 36.5% 
○ Average age 70.1
Why is it important? Health outcomes
● Own distinct disease process
● Interconnected to other diseases and various other forms of morbidity 
and mortality 
● Associated with:
○ Falls and fractures
○ Impairment of activities of daily living
○ Cardiac disease
○ Respiratory disease 
○ Cognitive impairment
○ Loss of independence







Why is it important? Healthcare costs 
● Sarcopenia associated with:
○ Increased risk of hospitalization
○ Increased cost of hospitalization
○ Increased total cost of healthcare 
○ Decreased quality of life
Why is it important? Healthcare costs





○ 5-item self-reported questionnaire; easily used in practice
○ Valid, consistent at identifying patients at risk for sarcopenia-
related adverse outcomes
● SarQoL
○ Predicts sarcopenia complications that impact quality of life
○ Assesses patient’s perception of disease
○ Not as well validated
○ May serve as proxy to measure treatment efficacy 
Diagnosis: SARC-F
Diagnosis: SARC-F
Diagnosis: Strength Testing 
● Grip strength 
○ Simple and inexpensive 
○ Requires calibrated dynamometer under defined test conditions 
with appropriate reference population
● Isometric torque methods
○ Measures lower extremity strength in patients with hand arthritis 
or deficits from stroke
● Chair sit to stand 
○ Proxy for leg strength
○ Easy to perform in clinical setting 
Diagnosis: Grip Strength
Diagnosis: Grip Strength 
Diagnosis: Grip Strength 
Diagnosis: Sit to Stand
Diagnosis: Muscle Mass
● Current area of study 
● Difficult to incorporate into practice currently 
● Dual-energy X-ray Absoptiometry (DXA)
○ Reproducible measure of appendicular skeletal mass 
○ Not portable and influenced by hydration
● Bioelectrical impedance analysis 
○ Estimates muscle mass based on whole-body conductivity
○ Math used needs validation
● Calf circumference 
○ Used by WHO 
○ Shown to predict survival and physical performance in older adults
Diagnosis: Muscle Mass
Diagnosis: Physical Performance
● Gait speed 
○ Recommended by EWGSOP2 due to feasibility and ability to 
predict sarcopenia related outcomes 
● Short Physical Performance Battery
○ Composite that includes gait speed, balance test, chair stand
○ Used mainly in research - takes at least 10 min to administer
● Timed Up and Go (TUG)




Prevention and Treatment: Diet 
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● Sarcopenia is a disease characterized by adverse muscle changes that cause
○ Decreased strength
○ Decreased muscle quantity and/or quality 
○ Poor physical performance in severe cases 
● Sarcopenia is associated with adverse health outcomes and increased costs
● EWGSOP2 provides framework for clinical diagnosis and evaluation 
● Treatment mainstays are exercise and dietary protein intake
● Role of the primary care doctor includes recognition, motivational 
interviewing, and awareness of social determinants 
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